Addex Therapeutics Ltd - Asset Resilience Ratio
Addex Therapeutics Ltd (ADXN) has an Asset Resilience Ratio of 0.09% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Addex Therapeutics Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Addex Therapeutics Ltd's Asset Resilience Ratio has changed over time. See ADXN book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Addex Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Addex Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.86K | 0.09% |
| Total Liquid Assets | $6.86K | 0.09% |
Asset Resilience Insights
- Limited Liquidity: Addex Therapeutics Ltd maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Addex Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Addex Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Addex Therapeutics Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Addex Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.06% | $6.50K | $10.68 Million | +0.04pp |
| 2023-12-31 | 0.02% | $848.00 | $4.64 Million | -0.02pp |
| 2022-12-31 | 0.04% | $3.17K | $8.28 Million | -0.04pp |
| 2021-12-31 | 0.08% | $17.14K | $22.54 Million | -0.25pp |
| 2020-12-31 | 0.32% | $64.93K | $20.18 Million | +0.28pp |
| 2019-12-31 | 0.04% | $13.97K | $33.03 Million | +0.02pp |
| 2018-12-31 | 0.02% | $7.98K | $42.21 Million | -0.35pp |
| 2017-12-31 | 0.37% | $11.29K | $3.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $2.89 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $4.00 Million | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more